164 results
SD
EX-1.01
PACB
Pacific Biosciences of California Inc
30 May 24
Conflict minerals disclosure
4:50pm
began with an evaluation of its suppliers that provided materials, components or products that became part of products PACB manufactured … records such as bills of materials and other product specifications, and performing a qualitative review of purchasing records and/or information
DEFA14A
PACB
Pacific Biosciences of California Inc
29 May 24
Additional proxy soliciting materials
9:52pm
Statement
☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐Definitive Proxy Statement
☒Definitive Additional Materials
☐ … of Filing Fee (Check the appropriate box):
☒No fee required
☐Fee paid previously with preliminary materials
☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
8-K
EX-99.1
PACB
Pacific Biosciences of California Inc
9 May 24
PacBio Announces First Quarter 2024 Financial Results
4:12pm
; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products
DEFA14A
PACB
Pacific Biosciences of California Inc
29 Apr 24
Additional proxy soliciting materials
8:17am
Statement
☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐Definitive Proxy Statement
☒Definitive Additional Materials
☐ … of Filing Fee (Check the appropriate box):
☒No fee required
☐Fee paid previously with preliminary materials
☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
8-K
EX-99.1
lz815r32u1h
16 Apr 24
PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance
8:08am
8-K
EX-99.1
9d6hzdbzscrq82kcdh79
15 Feb 24
PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results
4:07pm
8-K
EX-99.1
dnolqqv7mr
30 Oct 23
PacBio Announces Third Quarter 2023 Financial Results
4:06pm
D
uwxs7lb15gxikk3x 4fk
19 Oct 23
$84.76 mm in equity, sold $84.76 mm, 165 investors
4:10pm
D
v95q7xm
17 Aug 23
$85.00 mm in equity, sold $85.00 mm, 47 investors
3:52pm
8-K
EX-99.1
qjy19
2 Aug 23
PacBio Announces Second Quarter 2023 Financial Results
4:10pm
SD
EX-1.01
kdgnz08ct30pomsctl
24 May 23
Conflict minerals disclosure
12:00am
8-K
EX-99.1
pr5gg2l lam
2 May 23
PacBio Announces Record Revenue in First Quarter 2023
4:03pm